| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8711910 | Annals of Allergy, Asthma & Immunology | 2018 | 9 Pages |
Abstract
The use of omalizumab was associated with increased costs but no evidence of lower rates of clinically important outcomes. These results suggest omalizumab had limited effectiveness in our study population. Future studies should further explore subsets of patients most likely to benefit from omalizumab therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Mina PharmD, PhD, Wayne MPH, Gerald PhD, Matthew B. MD, PhD, Diana MSc, J. Michael MSc, Muhammad M. PharmD, MA, MPH, David N. MD, PhD, Tara MHSc, PhD,